The safety data strengthen the nonclinical foundation for ERNA-101, but the stock remains binary on IND clearance and eventual clinical data. Watch for the Q4 2026 IND submission and any updates on GMP manufacturing progress.
Price Chart
Executive Summary
Ernexa Therapeutics reported encouraging nonclinical safety results for its lead iPSC-derived cell therapy ERNA-101 across three IND-enabling studies: no adverse findings in a 50-day GLP repeat-dose toxicology study, no teratoma formation through six months in a tumorigenicity study, and no significant biodistribution signal in tumor-free animals. The company remains on track for a Q4 2026 IND submission for platinum-resistant ovarian cancer, with initial clinical data expected in Q4 2027.
Key Facts
- No ERNA-101-related adverse findings in a 50-day GLP repeat-dose toxicology study across all dose levels tested.
- No teratoma formation observed in ERNA-101-treated animals through the six-month tumorigenicity in-life phase.
- No significant ERNA-101 signal detected in tumor-free animals or non-tumor tissues in a five-week biodistribution study.
- Core IND-enabling safety studies complete; GMP manufacturing underway.
- Company remains on track for planned Q4 2026 IND submission for ERNA-101 in platinum-resistant ovarian cancer.
- Initial clinical data currently expected in Q4 2027.
Financial Impact
Preclinical safety results de-risk the ERNA-101 program; no financial figures disclosed.
Risk Factors
- Preclinical results may not translate to human safety or efficacy.
- IND submission in Q4 2026 is subject to regulatory clearance; delays or clinical holds are possible.
- Ernexa is a pre-revenue clinical-stage biotech with no approved products; capital needs are uncertain.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3371881 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $2.08 | awaiting T+5 | — | $1.94 (−6.51%) |
Oct 15, 2026 11d ago | 8-K | $2.09 $2.07 | ▼ −1.20% | ▼ −0.77% | $1.94 (−7.18%) |
Oct 1, 2026 25d ago | Press Release | $2.96 $2.49 | ▼ −15.88% | ▼ −17.18% | $1.94 (−34.46%) |
Sep 30, 2026 26d ago | Press Release | $3.20 $2.39 | ▼ −25.31% | ▼ −27.23% | $1.94 (−39.37%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Jul 14, 2026 14w ago | Press Release | $6.06 $5.43 | ▼ −10.40% | ▼ −9.10% | $1.94 (−67.99%) |
Jun 26, 2026 17w ago | 8-K | $7.03 $6.44 | ▼ −8.39% | ▼ −9.78% | $1.94 (−72.40%) |
Jun 17, 2026 18w ago | Press Release | $5.89 $6.30 | ▲ +6.96% | ▲ +8.00% | $1.94 (−67.06%) |
May 27, 2026 21w ago | Press Release | $11.14 $8.00 | ▼ −28.19% | ▼ −29.39% | $1.94 (−82.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers